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ABSTRACT  
Dendrimers have emerged as a powerful class of nanomaterials in the nanomedicine field due to their 
unique structural features: globular, well‐defined, highly branched and controllable structure, 
nanosize‐ scale, low polydispersity, and the presence of several terminal groups that can be 
functionalized with different ligands simulating the multivalency present in different biological 
systems. Although in its infancy, the application of dendrimers as therapeutics or theranostic tools in 
central nervous system (CNS) disorders is already significant and has opened promising avenues in 
the treatment of many conditions where the inherent “smartness” of the dendritic structures is being 
explored to effectively target the CNS. Here we present an overview of the past and future challenges 
of the use of dendrimers to respond to one of the ultimate challenges in the (nano)medicine field: to 
attain CNS repair and regeneration. 
Keywords: blood-brain-barrier (BBB), cell targeting, dendrimers, neurological diseases, 
neurodegenerative diseases, surface functionalization 
1. Considerations on Neurological Diseases 
According to the World Health Organization (WHO),1 it is estimated that 1 billion people worldwide 
are affected by a neurological disorder and, among these, 6.8 million people die every year as a result 
of these conditions. 
Central nervous system (CNS) disorders currently represent 7% of the global burden of disease when 
measured in disability-adjusted life-years (DALY) and, as the population ages, this is expected to 
rise.2 Pathologies of the CNS include vascular disorders such as ischemic stroke, structural disorders 
like spinal cord injury (SCI); infections such as meningitis; functional disorders such as migraines; and 
neurodegeneration such as Alzheimer's disease (AD). The common issue among them is the resulting 
neurological debilitation that typically occurs, reflecting to a high extent the limited capacity for the 
CNS to repair itself, especially at older ages.3 An injured neuron, either sensory, motor or 
interneuron, engages in an abnormal pathway that is difficult to overcome. The mechanism of 
neuronal dysfunction resulting from a trauma, neuronal degeneration, or demyelination, may involve 
alterations in ion channel activity, an imbalance in the membrane potential, oxidative stress, 
impaired mitochondrial function, cessation of neuronal communication, and ultimately death.4 
2. Overcoming Biological Barriers 
The early identification and diagnosis of a neuropathological status, as well as the protection and the 
recovery of the neuron and non‐neuronal cell population has been for long a critical challenge. 
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Nevertheless, the identification of CNS biomarkers of disease and cell ‐ related therapeutic 
molecules has tremendously increased over the past few years, which has led to another quest for 
the effective delivery of these therapeutic/diagnosis molecules to the afflicted neuronal and non‐
neuronal cells in a safe and controlled manner, as well as the fine‐tuning of the delivery profiles of 
therapeutics in a neuropathological scenario. This is extremely challenging because from the 
moment a therapeutic/diagnosis agent is administered until it reaches the target injured CNS cell, 
several barriers have to be overcome. 
The main and most‐studied barrier is the blood‐brain barrier (BBB). The BBB, also known as the 
neurovascular unit, is composed of brain capillary endothelial cells in association with astrocytes and 
pericytes, which together regulate relentlessly the bidirectional transfer of essential substances, 
while blocking the passage of harmful and foreign substances from the bloodstream to the CNS.5 
Molecules can cross the BBB by paracellular (i.e., between cells) or transcellular (i.e., across cells) 
diffusion. Because of the tight BBB junctions, paracellular diffusion does not occur to a great extent. 
For transcellular diffusion, different mechanisms are in place: a) receptor‐mediated endocytosis; b) 
carrier/transporter‐mediated endocytosis; c) adsorptive or fluid‐ phase endocytosis; and d) 
passive diffusion.6 It is recognized that the ability to enter the brain and the mechanism adopted are 
dependent on the molecule size, charge, and hydrophilicity. Only highly lipophilic molecules with a 
low molecular weight can passively diffuse across the brain capillary endothelial cells, while most of 
the high molecular weight and hydrophilic molecules cannot passively cross the BBB.7 Adsorptive 
mediated endocytosis contributes to the transport of positively charged substances, i.e., cationic 
molecules.8 For carrier/transporter ‐ mediated endocytosis, a form of facilitated diffusion, a 
molecule binds to a transporter on one side of the membrane resulting in the transport of the 
substance to the other side of the membrane, from high to low concentration. The receptor‐
mediated mechanism presumes the involvement of specific receptors expressed on the endothelial 
cells of the BBB.7 
Various strategies have been developed to enhance the ability of different compounds, otherwise 
excluded from the nervous tissue, to cross the BBB and enter the CNS when administered 
intravenously (i.v.).9 These can be divided into physiological methods, invasive techniques, 
nanomedicine approaches, or even combinatorial strategies. As a physiological approach, the 
receptor‐mediated delivery has been more explored where a specific ligand targeted to a particular 
receptor of the BBB is directly associated to the delivery molecule, significantly improving its entry 
into the CNS.10 Nanomedicine approaches take advantage of nanomaterials to serve as vectors for 
the agent of interest. Invasive approaches, like the disruption of the BBB by focused ultrasound, is a 
promising possibility,11 but its use must be carefully controlled to assure that the effect is transient 
and short in time so that it does not significantly increase the entry of plasma proteins and neurotoxic 
molecules, which may damage neuronal cells. Interestingly, in some CNS disorders, like stroke, the 
BBB is actually open in the area of the lesion in the aftermath of the insult12 for a period that can 
range from hours to a few days, which provides a natural window of opportunity for drug delivery. 
This is also the case in conditions that lead to an increased permeability of the BBB in the affected 
areas, such as sites of inflammation, infection, or tumors. In the latter case, the BBB is compromised 
for longer periods of time. 
An alternative to circumvent the BBB is to adjust the route of administration. There are various 
possibilities to administer a therapeutic drug in the body, which may occur locally or peripherally to 
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the intended target tissue/cell. However, there are always limitations associated to the procedure, as 
depicted in Figure 1. 
 
 
Figure1. Selected administration routes for dendrimers and other nanoparticles. The main 
advantages associated with each procedure are depicted in the green box and the main 
disadvantages in the red box 
 
The choice of the administration route has a profound effect not only on the accessibility of the drug 
to the target tissue/cell but also on its time of action and efficacy. To bypass the BBB there are various 
options such as an intracerebral (i.c.), subarachnoid, intraparenchymal, intrathecal, or intranasal 
delivery. Except for the intranasal delivery, the others are very invasive and not so prone to clinical 
translation. Nonetheless, they are effective and thus commonly found in pre‐clinical studies. Even 
so, the systemic administration route, such as i.v., continues to be the most used, despite the long 
pathway that the therapeutic/diagnosis molecules have to travel before reaching the CNS. Moreover, 
for systemic administrations there is a critical need to assure the protection and effective transport 
of the administered therapeutic agent (overcoming opsonization, immune recognition, and/or quick 
clearance). Finally, when a selected molecule reaches the nervous tissues, different cells are prone to 
uptake the delivered therapeutic. The ability to direct the therapy/diagnostic agent to a specific cell 
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type has obvious advantages and appropriate strategies are being pursued where targeting moieties 
are used. 
For the purpose of efficiently delivering a therapeutic and/or a diagnosis molecule to the CNS, 
engineered nanoparticles currently constitute one of the most powerful tools to cover some of the 
previously described requisites and to overcome cellular and extracellular barriers to delivery. An 
ideal nanocarrier for CNS therapeutic/diagnosis approaches should encompass a number of features, 
namely biocompatibility, the capacity to transport and protect its cargoes from degradation and/or 
rapid clearance (e.g., if systemically administered), the potential to reach the CNS, and specifically to 
target and deliver its cargo to the cell population of interest. Finally, biodegradability must also be 
equated, particularly in the context of regenerative therapies. Among the different delivery systems 
being explored—liposomes,13 polymeric micelles,14 linear polymers,15 quantum dots,16 iron oxide 
nanoparticles,17 and carbon nanotubes18—dendrimers/dendritic structures (Figure 2) are an 
emerging and particularly attractive class of nanocarriers for CNS drug delivery and diagnosis.19 
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Figure 2. Schematic representation of a dendrimer structure with three generations (G). 
 
In this review, we identify the currently existing dendritic systems, discussing their strengths and 
caveats in the context of attaining efficient therapeutic strategies for the treatment of neurological 
disorders. 
3. Dendrimers 
Dendrimers emerged from the “cascade molecules” , a new class of highly branched molecules 
initially reported by Vögtle et al. at the end of 1970.20 Then, Denkewalter, Tomalia, Newkome, 
Frechet, and coworkers further enlarged the complexity of these systems, giving rise to bigger 
structures, then renamed them as “dendrimers”.21 The word dendrimer comes from the Greek 
dendron (“tree” or “branch”) and meros (“part”), and refers to the characteristic organization of their 
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branched building units. Dendrimers consist of a) a bi‐ or multi‐functional central core, b) building 
units covalently attached to the central core and organized in layers called “generations” (G), and c) 
a large number of end functional groups on their periphery (Figure 2). 
The most researched dendrimers as vectors for CNS applications are the poly(amido amine) 
(PAMAM) dendrimers,22 but others like poly(propylene imine) (PPI),[10, 22, 23] poly(L‐lysine)‐
based (PLL),[22, 24] carbosilane,25 poly(ether)‐copoly(ester) (PEPE),26 phosphorus,27 poly(ether 
imine) (PETIM),28 and gallic acid−triethylene glycol (GATG) dendrimers29 have also been explored 
(Figure 3). These and other dendrimers present very appealing features to mediate the delivery of 
drugs and bioactives to the CNS due to their unique structural properties: a globular, well‐defined 
and very branched structure, as well as a low polydispersity, adaptable solubility, low viscosity, and 
controllable nanosize that allows for tight control and tuning of the size of the resulting dendritic 
nanoparticles (important when defining administration routes and/or the capacity to overcome 
certain biological barriers). Moreover, the abundance of peripheral functional groups allows the 
specific and controllable tethering of a great variety of bioactive ligands (Figure 4a), imitating the 
multivalency existing in several biological systems. In fact, this multivalency is the greater virtue of 
dendrimers. 
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Figure 3. Partial structure of some of the currently used dendrimers in CNS applications: a) PAMAM; 
b) PPI; c) GATG; d) PLL; e) carbosilane; f) phosphorous; g) PETIM; and h) PEPE dendrimers. 
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Figure 4. a) Dendrimer multifunctionalization and “dendritic box”. b) Dendritic nanoparticle (cargo = 
drug, nucleic acid, protein, peptide, among others). 
 
The enhanced effect that stems from the presentation of several and/or different bioactive molecules 
simultaneously at the same place causes an increase in the drug/ligand loading capacity that can 
contribute to the maintenance of drug levels in a therapeutically desirable range or an increase in the 
sensitivity and specificity of diagnostic systems. This high density of end functional groups also offers 
the possibility to link target molecules that can improve the delivery efficiency while decreasing side 
effects. Additionally, dendrimers can also cargo a molecule of interest by forming nanosized 
structures stabilized by non‐covalent interactions (Figure 4). From a biological point of view, 
dendrimers can be applied through a diversity of routes of administration.30 Furthermore, 
dendrimers present reduced macrophage uptake (particularly for lower generations/sizes), facile 
biological barrier crossing, and rapid cellular entry,31 all of which are tunable by changing the 
concentration, generation/molecular mass/size, and/or surface groups/charge of the dendrimers. 
All these properties make dendrimers very versatile and appealing nanocarriers, particularly 
presenting special advantages for transporting drugs across the BBB when in comparison with other 
nanomaterials. 
Dendrimers are synthesized through an iterative synthetic methodology that consists of a series of 
repetitive growth and activation steps. The two conventional approaches to synthesize dendrimers 
are the divergent and the convergent methods (Figure 5). 
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Figure 5. Classic strategies for the synthesis of dendrimers. 
 
The divergent synthesis (Figure 5a), also known as the “starburst” method or the “inside‐out” 
approach, was introduced by Vögtle20 and further developed by Tomalia[21] and Newkome.[21] It 
involves the growth of the dendrimers layer by layer from a multifunctional core site towards the 
periphery.32 The multifunctional core reacts with monomeric molecules or building units that 
contain one reactive and at least two inactive or protected branched sites to give the first dendritic 
layer or first generation dendrimer. Then, the surface/edge of the new molecule is 
activated/deprotected for subsequent reactions with more building units for expanding the 
dendrimers. The number of times this stepwise process is repeated will define the generation (G) 
number and, therefore, the dendrimer size. And it can be repeated several times until steric 
hindrances impede the reaction of all peripheral groups with more building units due to surface 
crowding for high generation dendrimers. Even so, this strategy has allowed for obtaining high 
generations in particular cases, namely, G9 for poly(phenylene) dendrimers,33 G10 for PAMAM,34 
G12 for phosphorus dendrimers,35 and even G13 for triazine dendrimers.36 The convergent approach 
(Figure 5b), established by Fréchet et al. in 1990,[21] can be considered as the reverse of the divergent 
approach. This strategy involves the synthesis of perfect branched and individual dendrons 
(dendrimer wedges), which finally are attached to a multifunctional core after 
activation/deprotection of their focal point, in an “inward” process.[32] 
The divergent strategy presents the disadvantage of building dendrimers with structural defects due 
to the higher number of reactions performed at the same time and therefore usually requires 
purification after each step.37 The probability of obtaining side‐products increases with generation, 
which further results in lower overall yields. Contrarily, in the convergent approach, since only a 
confined number of groups is active per step, the probability of structural defects is lower.37 
However, a major disadvantage is its low ability to produce dendrimers of higher generations due to 
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the steric hindrance between increased dendrons in the last step. Although an adequate choice of 
the multivalency and size of the core could reduce steric hindrance effects.37 
To conquer these drawbacks and the often tedious and time‐consuming processes of these classical 
strategies, new faster and simpler synthetic approaches have been reported, including “ click 
chemistry” ,38 “Lego”  chemistry,39 and accelerated,40 orthogonal40, 41 and chemo‐selective 
growth strategies,40 which render higher branching or number of terminal groups and reaction 
efficiency while reducing the number of reaction and purification steps. Methods that do not require 
any purification after each step because they only produce innocuous byproducts (e.g., water and 
sodium chloride), have been also reported.42 These improvements diminish the use of starting 
materials, chemicals, and side products. Consequently, these improved syntheses are less time‐ and 
cost‐consuming, as well as more environmentally friendly. 
In general, all these strategies yield products with well‐defined structures and low polydisperse 
sizes, which are quite engaging not only from a synthesis reproducibility point of view but also for 
reducing experimental variability in the different applications. In fact, this optimization and increased 
easy accessibility to more and more sophisticated dendrimers has led to the commercialization of 
different families of dendrimers while others are on the brink of this. As a consequence, the number 
of applications has exponentially increased, including biomedical ones. In fact, some diagnosis and/or 
in vitro dendrimer‐based technologies are already on the market. Namely, the Stratus® CS 
Instrument (Siemens Healthcare) that takes advantage of a PAMAM dendrimer‐based biosensor 
carrying a monoclonal sheep antibody for fast and accurate cardiac detention of patients with 
suspected myocardial ischemia and two PAMAM‐based transfection agents for in vitro assays 
(Superfect® (G6) and PriofectTM) marketed by Qiagen and Starpharma, respectively. A DNA chip 
(DendrisChipTM) based on phosphorous dendrimers has also been proposed by the biotech company 
Dendris for the detections of a broad range of viruses and pathogens with high sensitivity and 
specificity. Other dendrimers have already reached human clinical trial; such is the case for 
Gadomer®‐17 (also known as SH L 643 A; Schering AG), which is a PLL dendrimer holding 24 
gadolinium (III)‐DOTA chelate groups at its surface (commercial name Dotarem®; DOTA – 
1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetraacetic acid). This was the first dendrimer‐based 
product entering into clinical evaluation as a blood pool contrast agent for magnetic resonance 
angiography.43 However, despite the promising early clinical results, Gadomer®‐17 clinical testing 
was not pursued further, although it is currently being commercialized as a pre‐clinical research 
contrast agent. In cancer therapy research, DEP™ docetaxel emerged as a dendrimer‐enhanced 
version of docetaxel (Taxotere®) for solid tumor treatment by systemic administration. In pre‐
clinical studies, DEP® docetaxel showed greater anti‐cancer effects as compared to Taxotere®, and 
thus it is now in phase I clinical trial in patients with advanced solid tumors.44 Finally, VivaGel® from 
Starpharma is a G4‐PLL‐based dendrimer formulated as a water‐based mucoadhesive gel to be 
delivered vaginally. This gel was approved by the Australian Therapeutic Goods Administration in 
2014 and gained European regulatory approval for topical treatment and rapid relief of bacterial 
vaginosis in 2015. Phase III clinical trials are ongoing to evaluate its potential in prevention of 
recurrent bacterial vaginosis.45 Vivagel® is also being investigated as vaginal microbicide to prevent 
the transmission of genital herpes (HSV‐2), human immunodeficiency virus (HIV) infections, and 
other sexually transmitted infections including human papillomavirus (HPV), the causative agent of 
cervical cancer.46 It is also being used as a condom coating due to its antiviral and antibacterial 
properties (only available for the Australian market at present).47 
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4. Dendrimers as CNS Delivery, Imaging and Diagnosis Systems 
Due to the easy tuning regarding composition, structure, and size, dendrimers are versatile systems 
to serve as vectors for numerous biomedical applications, including brain delivery and diagnosis. 
They are being explored as promising carriers of chemical drugs, therapeutic nucleic acids (NAs), 
proteins and peptides, as well as macromolecular contrast agents and biosensor platforms for CNS 
therapies, imaging, and diagnosis (Figure 4). The strategies of preparation of the bioactive‐
dendrimer systems are briefly discussed in the following paragraphs, according to the type of 
bioactive that is being linked/transported. 
4.1 Chemical Drug Delivery 
Dendrimers present optimal guest–host properties for accommodation of different chemical drugs. 
These can be contained inside dendrimers (“dendritic box”  model, Figure 4a)48 through non‐
covalent interactions: electrostatic,49 hydrogen bonding,26 and, mostly, hydrophobic interactions, 
as in the case of some anticarcinogenic drugs used for the treatment of brain tumors.[23, 26, 50] 
Alternatively, drug conjugation to the dendrimer can be pursued. The large density of different 
functional surface groups on dendrimers, namely hydroxyl‐, thiol‐, amine‐, carboxylic acid‐, 
azide‐ , allyl groups, and so on, provide a unique chance for ionic coordination51 or covalent 
attachment of drugs, which can be directly tied to the dendrimers through different linkages.[22, 52] 
The conjugation approach is very appealing because it further allows the engineering of drug delivery 
systems susceptible to stimuli by linking the drug through cleavable chemical (pH or redox sensitive) 
or enzymatic bonds.53 Therefore, a better control of the kinetics of drug release can be achieved.[22, 
52, 54] The major downside of this approach is the increased complexity in the chemical design of the 
conjugates, as well as the direct exposure of the bioactives to the tissue environment upon 
administration. On the contrary, simply entrapped drugs into the dendritic box stay more protected. 
Nevertheless, a lower number of bioactives can be encapsulated, the guest molecules can 
prematurely diffuse out of the dendrimer, and/or their release kinetics cannot be strictly 
controlled.54 Since both approaches present their own pros and cons,55 some researchers have also 
evaluated the combination of both approaches simultaneously.54 
4.2 Nucleic Acid Delivery 
Cationic dendrimers have the ability to complex and protect NAs in compact structures called 
dendriplexes through electrostatic interactions.56 Because of this, dendrimers are also appealing 
non ‐ viral vectors that can help to surpass the different extra ‐  and intracellular barriers 
encountered in order to efficiently deliver exogenous therapeutic NAs, such as plasmids[10, 22] and 
siRNA,[22, 25] into CNS cells. Moreover, the possibility of multifunctionalization in dendrimers also 
allows using them to act as co‐delivery systems of different bioactive simultaneously. For instance, 
the delivery of NAs and chemical drugs has been explored, as will be detailed in section 6.[24] 
4.3 Protein and Peptide Delivery 
Although very scarcely explored yet, dendrimers have also been tested as protein57 and peptide58 
carriers. Concerning the delivery of proteins, the direct conjugation of the protein to the dendrimer 
is not suitable because of their similar molecular weights and sizes, so complexation and/or 
encapsulation are more adequate strategies. In the reported dendritic systems for protein or peptide 
 Version: Postprint (identical content as published paper) This is a self-archived document from i3S – Instituto de 
Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our 
publications, please visit http://repositorio-aberto.up.pt/  
 
A
0
1
/0
0
 
delivery, the main interactions established between the carrier and cargoes are electrostatic. 
Nevertheless, especially in the case of proteins, hydrophobicity was also found to play an important 
role in this process.59 To the best of our knowledge, for now, there is no report exploring dendrimers 
as delivery vehicles of protein or peptides in the context of CNS. 
4.4 Macromolecular Contrast Agents 
For brain medical diagnosis, an interesting case of dendrimer conjugation is the covalent attachment 
of diagnosis agents for the preparation of dendritic macromolecular contrast agents for X‐ray 
imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI).19 The aim is 
to obtain large molecular weight contrast agents to improve the image contrast, stability, water 
solubility, biocompatibility, and pharmacokinetics, while minimizing toxicity and required dose. The 
most widely explored dendritic contrast agents for MRI are based on small paramagnetic 
gadolinium(III) chelates (Gd(III)‐DTPA (DTPA = diethylenetriaminepentaacetic acid, Magnevist®) 
and Gd(III) ‐ DOTA (Dotarem®)) conjugated to dendrimers.60 Additionally, organometallic 
complexes of dendrimers and dendritic nanoparticles with heavy isotopes of iodine have also been 
investigated as X‐ray contrast agents.61 Nevertheless, to the best of our knowledge, dendrimers 
have never been applied as X‐ray macromolecular contrast agents in the brain imaging context. 
Therefore, this would be an interesting application to be explored, since multivalent dendrimers 
represent one of the most appealing systems to take manifold contrast agent moieties,60, 62 as well 
as to concomitantly join target molecules, offering a sole chance to enhance site‐specific image 
contrast.63 
4.5 Biosensors 
The previously discussed guest–host properties of dendrimers also allow accommodating molecular 
probes, by encapsulation or covalent conjugation. This, together with the possibility of fine tuning 
and tighter control of their chemistry composition and architecture (i.e., core, backbone, and surface 
groups), make dendrimers very attractive platforms for the design and development of high 
sensitivity sensors.64 Moreover, dendrimers can help to surpass the problems related to the response 
variability due to the limited sensor molecule loading efficiency, limited accessibility of the probes, 
poor control over uniform spacing among the probes, and a loss of functionality due to irregular 
orientation of the probes. In fact, researchers have demonstrated that dendritic macromolecules 
show improved sensitivity and accessibility of the probe for the target analyte and high stability, 
minimize non‐specific binding, and provide a low variability in their response. Therefore, the 
development of dendrimer‐ based sensors is an advantageous way to obtain higher sensor 
performances and reduce the whole preparation cost. Dendrimers could, therefore, convert into very 
interesting tools for functional CNS imaging and diagnosis.65 
5. Tailoring Dendrimer ‐ Based Delivery Systems for CNS 
Applications: (Bio)functionalization, Targeting and Labeling 
The tunable chemistry of dendrimers permits a precise “chemical makeup” that allows the design, in 
principle, of an almost unlimited number of molecules. This, together with the possibility of an 
accurate chemical multi‐ decoration with several (bioactive) ligands and/or target molecules, 
permits dendrimers to act as “smart” nanosystems for the efficient and site‐specific delivery of 
several agents to the CNS. 
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5.1 (Bio)functionalization 
Depending on the desired application, target cells/tissue, type of administration, and characteristics 
of the bioactive to be linked and/or carried, dendrimers can be properly (bio)functionalized using 
different strategies. 
To interfere in Aβ‐amyloid fibril formation, which might represent a new method to address the key 
pathology in AD, amine‐terminated G4 and G5 PPI dendrimers were decorated with maltose and 
maltotriose by reductive amination in a one ‐ pot approach.[23] With the same objective, 
morpholine was introduced on the surface of G3 GATG by means of Cu(I)‐catalyzed azide‐alkyne 
cycloaddition (CuAAC, click chemistry).29 
In the context of drug release, previously mentioned strategies aimed to afford a control of kinetics 
of drug liberation have also been tested for brain delivery. For example, the anti‐carcinogenic 
doxorubicin (Dox) has been attached to G4 PAMAM dendrimers via an acid‐sensitive cis‐aconityl 
linkage[22] and to G3 dendrigraft poly(L‐lysine) (DGL) through pH‐trigged hydrazone bond,[24] 
what favors a fast Dox release in the acidic tumor environments. However, these acid‐ labile 
linkages are not an adequate approach for the treatment of CNS diseases, like neurodegenerative 
disorders, in which the pH persists neutral. Ester linkages are the preferred option in these cases 
and/or when a more prolonged drug release under acid and neutral pH is desired. Moreover, one can 
also play with the nature of the used linker/spacer to attach the drug to the dendrimer to further tune 
the hydrolysis rate of the ester group, and thus to maintain the drug release during the desired period 
of time. Iezzi et al. linked fluocinolone acetonide (a drug for attenuation of neuroinflammation in the 
retina) to hydroxyl‐terminated G4 PAMAM (G4 PAMAM‐OH) via an ester bond using a glutaric 
spacer, observing a sustained drug release for a period over 90 days.[22] On the contrary, Sk and co‐
workers used the ester strategy to link two anticancer drugs (estramustrine and podophyllotoxin) to 
the same type of dendrimer (G4 PAMAM‐OH) through a succinic acid linker, obtaining a sustained 
release during a significantly shorter time period (6 days).[52] 
In a similar manner, disulfide bonds were also explored as degradable (reductible) linkages through 
the use of different linkers/spacers. For instance, a small linker, namely succinimidyl 3‐ (2‐
pyridyldithio)propionate (SPDP), has been commonly explored to hang different brain drugs and/or 
bioactives to dendrimers via disulfide bonds. Such is the case of N‐acetyl cysteine (NAC)[22] 
(attenuator of neuroinflammation) and thiol‐ functionalizated valproic acid[22] (excitotoxicity 
attenuator), which were attached to G4 PAMAM dendrimers using this dithio‐spacer. On the other 
hand, Kaneshiro et al. used the dithio‐spacer (4‐succinimidyloxycarbonyl‐α‐methyl‐α‐[2‐
pyridyldithio]toluene) (SMPT) to hang Dox to G3 PLL dendrimers via the disulfide linkages strategy 
as well, where PLL was thiolated with 3‐mercaptopropanoic acid) a priori.[24] More stable amide 
bonds were used to link the anti‐carcinogenic curcumin and methotrexate to G3 and G5 PAMAM 
dendrimers, respectively, via the frequently used carbodiimide chemistry.[22, 66] Also, boron‐10‐
enriched methylisocyanato polyhedral borane anion was connected to G4 and G5 PAMAM via stable 
carbamide linkers in order to obtain the corresponding boronated dendrimers for neutron capture 
therapy (NCT) of brain tumors.[52, 67] 
5.2 Overcoming the BBB 
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Dendrimers can gain access to the CNS microenvironment by either passive or active targeting. The 
passive targeting can occur either as a result of the enhanced permeability and retention (EPR) effect 
or as a consequence of the selected administration route. The EPR effect relates to the propensity of 
molecules to preferentially accumulate at sites of increased vascular permeability, such as sites of 
inflammation, infection, or tumors. However, as previously mentioned, after certain insults (like in 
the case of stroke or a traumatic SCI) the BBB at the injury site is compromised for a limited period of 
time. Therefore, due to the EPR effect, systemically administered dendrimers have the potential to 
overcome the BBB and passively and effectively target the diseased brain. Nevertheless, the EPR‐
dependent molecule accumulation is slow, and thus only a small portion of the circulating molecules 
actually reaches tumors or sites of inflammation/infection, while the majority tends to accumulate in 
the liver and kidneys (filtering organs) or even in the lungs and heart in the case of large entities, like 
particulate systems. As previously mentioned, an additional strategy to surpass the BBB is to select 
an appropriate route of administration (Figure 1) that, per se, avoids this barrier. However, the 
invasiveness of some of these routes can be an obstacle. 
Therefore, to overcome these drawbacks, dendrimers can be actively functionalized on their surface 
with targeting ligands that selectively guide their binding to receptors or specific molecules 
overexpressed at the target cell, tissue, or organ.68 In this regard, several BBB receptor‐mediated 
transport mechanisms have been exploited as the route for CNS access. The brain capillary 
endothelial cells, as well as many malignant tumor cells, overexpress transferrin receptors (TfR), 
which renders the transferrin (Tf) family as useful targeting ligands to facilitate the BBB transport or 
gain access to brain tumors. The Tf family is a group of glycoproteins with the ability to bind and 
transport non‐heme iron, although some homologues have evolved different functions.69 Huang 
et al. targeted a poly(ethylene glycol) (PEG)‐modified G5 PAMAM (G5 PEG‐PAMAM) dendrimer 
with Tf that was able to transport NA to the brain following an i.v. administration.70 In another study 
from Somani et al., a Tf‐bearing G3 diaminobutyric PPI dendrimer (DAB) was able to increase the 
dendrimer cellular uptake and transgene expression by cancer cells overexpressing TfRs, as 
compared to non‐functionalized dendrimers, both in vitro and in vivo after an i.v. injection.[10] 
Using the same G5 PEG‐PAMAM, Huang et al. also explored the use of lactoferrin (Lf), a single‐
chain iron‐binding glycoprotein, as a brain targeting ligand. These authors demonstrated the 
improved ability of Lf‐functionalized/targeted complexes to cross an in vitro BBB model, as well as 
their in vivo brain targeting ability via an i.v. administration, in comparison with their non‐
functionalized or Tf‐conjugated counterparts.71 The dual brain targeting was also investigated by 
the combined use of Tf and wheat germ agglutinin (WGA) or tamoxifen (TAM). WGA is a lectin with 
a strong affinity to the brain capillary endothelial cells and tumor cells, but with a low affinity for 
normal tissues. Likewise, TAM is an estrogen receptor modulator with a suggested improved BBB 
transport. Both the Tf/WGA and Tf/TAM modified PAMAM dendrimers showed a synergistic BBB 
targeting effect and, therefore, a higher BBB transportation and payload release to the avascular C6 
glioma spheroids in vitro.[22, 50] Despite the success of all the examples described above, the use of 
Lf and Tf as targeting ligand can be compromised by the competition with their endogenous 
equivalents. In this regard, other recent studies have demonstrated the use of HAIYPRH (T7) peptide 
to specifically target the TfR with a similar affinity as Tf.72 Moreover, T7 peptide and Tf bind to 
distinct sites on the TfR and thus, they do not compete for the receptor binding. Using a PEGylated 
G3 DGL dendrimer modified with the T7 peptide, the Jiang group has demonstrated the brain‐
targeted delivery of anti‐tumoral therapeutics in an orthotopic human glioma model, providing new 
therapeutic opportunities to brain tumor treatment.[24] 
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Apart from the Tf family of ligands, additional brain targeting molecules have been probed. 
Angiopep‐2 is a peptide that binds to the low‐density lipoprotein receptor‐related protein 1 
(LRP1) that is ubiquitously expressed in the CNS and takes advantage of a receptor‐mediated 
transcytosis mechanism to cross the BBB. This peptide possesses a higher BBB penetration capability 
than other proteins, such as Tf and Lf. Angiopep‐2 has been used to mediate the target delivery of 
PAMAM and DGL dendritic structures in CNS disorders, such as brain cancer or Parkinson disease 
(PD).[24, 73] In another study, a 29‐amino‐acid peptide derived from the rabies virus glycoprotein 
(RGV29) was shown to be an effective brain targeting ligand as well. In a similar manner to its parent 
protein, RVG29 peptide binds specifically to the nicotinic acetylcholine receptor (nAchR) present on 
neuronal and brain capillary endothelial cells, and when linked to the surface of PAMAM it was able 
to mediate in vivo the efficient dendriplex accumulation and reporter gene expression in the brain 
upon i.v. administration.74 
From the point of view of the chemical strategies explored to attach the discussed targeting moieties 
to dendrimers, less labile bonds (like carbamates, amides, imines, and thioethers, among others) 
than those used in the majority of the cases described for the biofunctionalization/drug conjugation 
have been explored. In fact, the most commonly used strategy to tether the above‐mentioned brain 
targeting ligands to dendrimers was through the widely known bifunctional PEG presenting N‐
hydroxysuccinimide (NHS) and maleimide (MAL) as terminal groups (NHS‐PEG‐MAL). This 
approach supposes the establishment of an amide bond between the dendrimer and PEG dendrimer, 
and of a thiosuccinimide linkage between the PEG and the protein/peptide.[22, 24, 70, 71, 73-75] The 
exploration of PEG as a linker has several functions: on one hand, it forces the exposure of the 
targeting moiety, and on the other hand, it improves biocompatibility, provides longer circulation 
times, and reduces immunogenicity while increasing water‐solubility and enhancing the structural 
stability of the targeted systems. Although this is the most resourced strategy to tether targeting 
moieties to dendrimers, there are also few groups that have explored alternative approaches. For 
instance, in the aforementioned work from Somani et al., Tf was attached to G3 DAB via a dimethyl 
suberimidate (DMSI) cross‐ linking agent.[10] Also, it is worth mentioning the particular case 
reported by Li et al. where the dendrimer was used as a “dendritic box” to entrap TAM, used here as 
a targeting moiety.[22] 
5.3 Tumor Cell Targeting at the CNS Level 
In tumors, the EPR effect appears and the BBB permeability increases mainly as a consequence of 
cancer angiogenesis and extensive production of vascular mediators that facilitate extravasation. 
The newly formed vessels are usually abnormal and present large fenestrations. Consequently, in 
such settings, dendritic structures or dendritic‐based nanoparticles with suitable size, less than 100 
nm,76 can enter the brain tissue via endothelial gaps. Once within brain tissue, dendrimers for anti‐
tumoral therapy should recognize their target—brain tumor cells. For this, several groups have 
explored a number of brain‐tumor‐targeting ligands that specifically bind to different proteins on 
the surface of brain tumor cells. The most studied are the epidermal growth factor receptors (EGFR), 
integrins, and extracellular matrix (ECM) modulators. 
The EGFR and its mutant isoform EGFRvIII are transmembrane receptors expressed at high levels in 
various types of tumors, including brain tumor cells. The cetuximab (C225) antibody, specific for both 
wild‐type EGFR and EGFRvIII, has been probed for glioma targeting by Barth and colleagues. They 
reported the efficacy of C225‐PAMAM dendrimers carrying around 1100 boron atoms (B1100), 
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i.c. ‐ administered by convection ‐ enhanced delivery (CED), to significantly increase B1100 
accumulation in brain tumor tissues in comparison to healthy brain tissues, assuring the success of 
boron neutron capture therapy.[67] Moreover, they also demonstrated that direct i.c. administration 
of C225‐conjugated PAMAM‐methotrexate dendrimers by CED to glioma‐bearing rats resulted 
in a specific molecular targeting of the tumor.66 Other EGFR/EGFRvIII targeting moieties also 
investigated include monoclonal antibody specific to EGFRvIII, such as the EGF[52] and L8A4.[67] In 
these cases, the approach followed to decorate G4 and G5 PAMAM dendrimers with the brain‐
targeted antibodies, consisting of the aforementioned SPDP linker together with a N‐ (K‐
maleimidoundecanoic acid)hydrazide (KMUH).[52, 66, 67] PAMAM dendrimers were 
functionalizated with thiols through the attack of its primary amines to the succinimidyl group of the 
SPDP, while maleimides were introduced in the antibodies via the KMUH linker. Then, targeted 
dendrimers were obtained by reaction between both groups (thiols from PAMAM and maleimides 
from antibodies). 
Integrin expression, particularly integrin αvβ3, is prominent in glioma tumors but not on normal brain 
cells. The cyclic arginine–glycine–aspartic acid (RGD) peptide and its analogs have been widely 
investigated as ligands for integrin and, therefore, for glioma targeting strategies. Previous studies 
showed that i.v.‐ administered RGD‐modified dendrimers are capable of enhancing tumor 
penetration and accumulation, resulting in a general anti‐tumor effect of the chemotherapeutic 
drug Dox.[22, 24] 
Chlorotoxin (CTX) is a 36 amino‐acid peptide purified from the Leiurus quinquestriatus scorpion 
venom that binds with high affinity to the matrix metalloproteinase‐2 (MMP‐2) preferentially 
up‐regulated in tumor cells of the neuro‐ectodermal origin. Huang et al. exploited the PAMAM‐
CTX conjugates to carry a plasmid encoding for tumor‐necrosis‐factor‐related apoptosis‐
inducing ligand (TRAIL) into intracerebral glioma‐bearing mice. Upon intratumoral administration, 
these conjugates were able to increase their accumulation in brain tumor tissues and provoke a more 
widely extended apoptosis as compared to the group of animals treated with the commercially 
available drug temozolomide (chemotherapy drug).[75] 
Other studies exploited the potential of using D‐glucosamine as both BBB permeability enhancer 
and tumor targeting agent,26 as well as the use of cationic arginine residues,77 thiamine,[23] 
polysorbate 80 surfactant,[23] and the fibrin‐binding peptide CREKA,[22] as brain tumor targeting 
molecules. 
With regards to the chemical approach for carrying out the targeting in these last few examples, while 
RGD peptide,[22, 24] CREKA[22] and CTX[63] were linked via the well‐known and previously 
described NHS‐PEG‐MAL strategy to the dendrimers, glucosamine and some hydroxylated target 
molecules, such as polysorbate 80 and thiamine, were conjugated to G2 PEPE and G5 PPI dendrimers 
by using disuccinimidyl carbonate26 and carbonyl diimidazol (CDI),[23] respectively. 
5.4 In Vitro and In Vivo Tracking 
In order to follow the biodistribution of the dendritic delivery systems in vitro and in vivo, these can 
also be tagged with fluorescent dyes or radioactive atoms. Among the fluorescent dyes, the most 
widely used are fluorescein,[22] Cyanine 5 (Cy5),[22] boron‐dipyrromethene (BODIPY),[70, 73, 75] 
and rhodamine26 derivatives, although others labels like Alexa Fluor® 647 or IR783 have also been 
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used.4, 78 Nowadays, all these fluorescent dyes are sold with suitable functional groups to obtain an 
easy and stable attachment to the different terminal dendritic groups. In the majority of the cases 
summarized in this review, the most used ways to tag the dendrimers were based on carbodiidime, 
NHS, and isothiocyanate chemistry. 
To track the in vivo distribution of the dendritic systems, these can also be radiolabeled. Examples 
include the G5 PAMAM70, 74 and G3 DGL[22] dendrimers, which were radiolabeled with 125I via the 
commonly used 125I‐Labeled Bolton‐Hunter reagent. 
6. Applications of Dendrimers in the CNS 
The incidence of CNS diseases, especially those related to aging, has sharply increased in recent years 
due to the increment in life expectancy. This has put great pressure in the development of CNS 
therapeutics and its effective delivery. 
To support the use of dendrimers as promising delivery vectors to the CNS it is important that their 
mechanism of action is understood. To investigate the uptake of dendrimers specifically by the key 
cellular unit of the nervous system—the neuron—the process and kinetics of internalization of these 
macromolecules has been studied. Different endocytic mechanisms for PAMAM dendrimers have 
been observed in hippocampal neuronal cell cultures, including clathrin‐ and caveolae‐mediated 
internalization.79 The process appears to be dependent on the chemical surface modification of the 
PAMAM, as described by Hugh and colleagues, where unmodified (positively charged) and folic acid 
decorated dendrimers were internalized by both clathrin and caveolae endocytosis, while neutral and 
anionic dendrimers were not internalized. This lack of neuronal association observed for the latter 
has been explained by differences in the dendrimers' net charge. Functionalization of 50% of the 
amine surface groups with PEG led to neutral dendrimers, while the modification of 30% of amine 
surface groups with acrylate anionic groups rendered negatively charged dendrimers. In this context, 
another study has addressed the uptake of nanoparticles composed of 
carboxymethylchitosan/PAMAM dendrimers (CMCht/PAMAM) in CNS neuronal and mixed glial cell 
cultures. The results showed that, similarly to what was observed for all three glial cell types 
(oligodendrocytes, astrocytes, and microglia), hippocampal neurons were able to internalize 
dendrimers periodically given to the cultures for 1 week.80 The distinct rates of internalization were 
attributed to differences in proliferation, endocytic capacity, and different functions of each cell type; 
for example, the highest internalization for microglia was attributed to its phagocytic function. 
As previously commented, with the aim to increase the efficiency in crossing the BBB, dendrimers 
can be targeted with specific BBB ligands. This was illustrated in the case of PAMAM modified with 
the Angiopep‐2, a peptide recognized by the LRP1, which is abundantly present in the BBB 
endothelial cells.[73] This strategy resulted in an increased accumulation of the dendrimers in the 
mouse brain, 2 hours after i.v. administration, when compared to the unmodified PAMAM. However, 
the contribution of the PEGylation was not assessed in this study. Different brain structures were 
then analyzed, and while PAMAM was present at the cortex and caudate putamen, PAMAM‐
Angiopep was additionally present at the hippocampus and substantia nigra. 
When reaching the CNS after successfully crossing the BBB, the dendriplexes/nanoparticles must 
move through cells and tissues, i.e., these must diffuse through the parenchyma. A very interesting 
study using G4 PAMAM and 2‐hydroxydodecyl modified G4 PAMAM (C12‐PAMAM) dendrimers 
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showed that the 25% surface amine groups modification with this C12‐lipid induced in vitro toxicity 
and prevented parenchymal diffusion in vivo, while G4 PAMAM was most adequate for penetrating 
the brain parenchyma without causing toxicity or interfering with neural activity, as demonstrated 
by electrophysiological studies.4 
In the following paragraphs, the dendrimer‐based therapeutic and theranostics explored so far in 
the context of CNS are reviewed and discussed in detail. 
6.1 Vascular Diseases 
Treating neuronal damage after a cerebrovascular accident is a challenging issue and for this reason 
it is considered a major vascular disease. A cerebrovascular accident occurs due to an occlusion of a 
major artery (ischemic stroke) or rupture of a blood vessel (hemorrhagic stroke). In both cases, the 
therapeutic options available are reduced. Further challenges result from the limited window of 
opportunity to interfere with the pathological mechanism and the difficult access of therapeutics to 
the afflicted neurons. 
A recognized experimental model for ischemic stroke is to transiently occlude the middle cerebral 
artery with a monofilament.81 This and other models82 have allowed the study of neuroprotective 
therapies based on, for example, RNA interference (RNAi) strategies. An and colleagues reported the 
delivery, by a tail vein injection, of apoptosis signal‐regulating kinase 1 (Ask1) shRNA plasmid using 
a G3 DGL dendrimer with the aim to interfere with the mitogen‐activated protein kinase (MAPK) 
cascade signaling pathway after transient ischemia.83 To target the dendriplexes to the brain, DGL 
was decorated with dermorphin (an m‐opiate receptor agonist), which significantly elevated the 
relative accumulation of shRNA plasmid in the brain as followed by in vivo bioimaging. Nanoparticles 
were detected in ventricle, hippocampus, cortical layer, substantia nigra, and corpus striatum. As a 
measure of neuroprotective effect, the cerebral infarct volume was analyzed, resulting in a decreased 
value that reflected the efficient decrease of Ask1 expression by RNAi. Other similar NA‐based 
neuroprotective strategies in ischemia have been performed by means of arginine‐modified 
PAMAM dendrimers (e‐PAM‐R) as vectors for the high mobility group box 1 (HMGB1) siRNA 
delivery after intranasal administration,[22] and also by the use of carbosilane dendrimers to deliver 
hypoxia‐inducible factor (HIF1‐alpha) siRNA after induced hypoxia in cultured cortical neurons as 
a proof of concept.[25] Moreover, a PAMAM‐dexamethasone conjugate to deliver the heme‐
oxygenase‐1 (HO‐1) gene into the ischemic brain by stereotaxic injections was also reported.[22] 
In this study, dexamethasone was used to convey anti‐ inflammatory effects84 and also to 
simultaneously aid gene delivery as it binds to glucocorticoid receptor complexes, increasing nuclear 
localization.85 Overall, the outcome of the therapies was very positive, since the dendrimers showed 
a superior performance when compared with commercial transfection agents, as well as a 
therapeutic effect with a significant decrease in infarct volume, which opens new possibilities for 
gene therapy in stroke using dendrimers as delivery vectors. 
Another example from Kannan and co‐workers shows the use of a G4 PAMAM‐OH to reach the 
injured brain after global ischemia induced by hypothermic circulatory arrest in a canine model.[22] 
Upon i.v. administration, biodistribution studies revealed the dendrimers' presence in brain regions 
vulnerable for glutamate excitotoxicity, such as the hippocampus, cerebellum, and cerebral cortex. 
It was observed that dendrimers were selectively taken up in the injured hippocampal dentate 
granule cell layer, in cerebellar Purkinje and granule neurons, and in microglia. This study associates 
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excitotoxicity with dendrimer neuronal uptake, which is relevant for reaching the injured neuron 
population and ultimately in novel nanomedicine‐based therapies. 
6.2 Neurodegenerative Diseases 
Millions of people are affected worldwide by neurodegenerative diseases, being AD and PD the 
diseases with the higher incidence. The risk of developing a neurodegenerative condition increases 
dramatically with age. This is a commonly accepted reality for AD, which occurs due to the amyloid 
beta (Aβ) accumulation in the brain, leading to dementia. The number of patients and relatives 
affected, directly or indirectly, is enormous and, therefore, the research efforts on AD are vast. In the 
field of dendrimer‐based nanomedicine, AD fulfils a big piece of the research focus. For example, 
different studies have addressed the effect of distinct dendrimers on Aβ formation envisaging a 
future application on AD therapy. By using cationic phosphorus dendrimers[27] or the GATG 
dendrimers decorated with terminal morpholine groups,29 the interaction with Aβ was detected, 
and a closer inspection showed alterations in the aggregation pathway. Dendrimers influence on Aβ 
aggregation and disruption of mature fibrils prompted a study in a neuroblastoma cell line where a 
G3 PLL dendrimer was able to protect cells from Aβ toxicity and in vivo studies, using rats after 
unilateral intracerebroventricular injection, showed the presence of these dendrimers in different 
brain cell populations, like the hippocampal and cortical neurons.[24] This should have implications 
in AD pathology because the widespread localization of the dendrimers should be able to reach the 
disperse Aβ brain accumulation, impairing the amyloidogenic cascade and decreasing the 
pathological process. Also in AD research, sialic acid‐PAMAM conjugates were prepared to mimic 
the cell surface gangliosides known to have affinity for Aβ. This resulted in a lower toxicity induced 
by Aβ, leading to higher cell viability in a differentiated neuronal cell culture since the sialic acid‐
PAMAM functioned as a sequestering agent for A β .86 This suggests that specific dendrimer 
modifications may further enhance their ability to interact with abnormal Aβ. Another study using 
PPI glycodendrimers with either an electroneutral or a cationic maltose shell reduced in vitro the 
neurotoxicity of Aβ.[23] These two PPI maltose dendrimers reach the brain when administered 
intranasally and decrease the total burden of Aβ in transgenic AD mice. However, the PPI dendrimer 
with a cationic maltose shell induced an unexpected and unexplained cognitive decline in non‐
transgenic control mice. On the other hand, the electroneutral maltose dendrimer did not show any 
harmful effects to the mice used in this study. This highlights the fact that it is always important to 
exclude possible neurotoxic effects and, preferably, to perform tests using different methodologic 
approaches as well as assessments at different time points. 
Another possible application of dendrimers in neurodegenerative diseases has been explored in the 
context of PD. PD is a degenerative neurological disorder which affects neurons expressing dopamine 
in the substancia nigra of the brain, leading to motor symptoms. The therapeutic effect of human‐
glial‐cell‐line‐derived neurotrophic factor (hGDNF) complexed with a G5 PAMAM and targeted 
with Lf has been assessed in two different PD models (the 6‐hydroxydopamine (6‐OHDA) and the 
rotenone‐ induced chronic model).[22, 75] Behavior recovery with improvement of locomotor 
activity, reduction of dopaminergic neurodegeneration, and enhancement of monoamine 
neurotransmitter levels were achieved after i.v. administration, without changes in 
monocytes/macrophage levels as a toxicity evaluation parameter. Another strategy in PD for 
effective brain‐targeting gene delivery is the use of DGL bound with the angiopep‐2 ligand 
recognized by the LRP1, which is widely expressed on BBB endothelial cells. Multiple intraperitoneal 
injections of nanoparticles transporting a gene encoding for hGDNF resulted in improved locomotor 
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activity without changes in body weight.[24] All these reports show promising data in the treatment 
of PD. 
6.3 Neuroimmunomodulation 
The noteworthy ability of PAMAM dendrimers to target neuroinflammatory cells, even without 
specific ligands, has led to some interesting applications.22 As an example, the therapeutic NAC was 
delivered i.v. in a rabbit model of cerebral palsy using PAMAM as delivery vector. NAC in a soluble 
form did not show protective effects, while a lower dose of NAC associated to G4 PAMAM‐OH 
dendrimer was able to protect the brain by specifically reaching activated microglia and astrocytes, 
diminishing neuroinflammation and, consequently, protecting neurons.[22] This was ultimately 
shown to increase motor function of the animals. Moreover, this study also suggests that besides the 
influence of surface modifications that dictate the interactions of the dendrimers with distinct cells, 
the disease state and stage of pathology may as well influence the extent of the dendrimers uptake 
by different cells. The same compound, NAC, was also systemically delivered by PAMAM‐OH 
dendrimers in a mouse model of neonatal brain injury showing a shift in dendrimer co‐localization 
during the first 5 days from astrocytes and oligodendrocytes to activated microglia.[22] 
Unfortunately, the neuronal population was not assessed in this study. 
Vaccines for CNS infections are another area where dendrimers have been applied with interest. This 
is the case for rabies, a neurotropic infection, where PETIM dendrimers were selected to complex 
with the rabies virus glycoprotein gene.28 These dendriplexes were used to immunize mice after 
intramuscular administration with success since the viral titters of the nanoformulation were 
significantly increased when compared to control mice immunized with only the plasmid‐based 
rabies vaccine. Additionally, after an intracerebral rabies virus challenge, mice treated with the 
dendriplex showed 100% survival in contrast to the 60% survival for the control delivery without the 
dendrimer. 
6.4 Neuroinfection 
Dendrimers are also recognized in various publications as having therapeutic activity against prion 
diseases.[22, 27, 87] This disease in humans, called Creutzfeldt–Jakob disease (CJD), is caused by the 
accumulation of abnormal prion proteins that usually affect the occipital cortex, cerebellum, and 
supranuclear pathways leading to CNS dysfunction. In these studies, different dendrimers (PAMAM, 
PPI, PEI and with different generations ranging from G3 to G5) were used. Dendrimers have been 
found to be beneficial in this context by eliminating prion protein in scrapie form from cells, although 
requiring high density of reactive surface groups in the dendrimer composition irrespective of its 
charge as stated by McCarthy and colleagues.88 
Also regarding infection, HIV‐1 can cause dementia when the virus reaches the CNS. Antiretroviral 
therapy does not reach the CNS as readily as to other systems,89 which has an impact on the CNS 
infection. The use of gene therapy with siRNA delivery mediated by dendrimers has been 
investigated. Carbosilane dendrimers were already successfully evaluated in different in vitro 
experiments for the delivery of siRNA to decrease viral activity[25] as well as in vivo, after a retro‐
orbital vein injection, showing a very good biodistribution in the brain.[25] However, it remained to 
be determined if in vivo these dendriplexes would achieve gene‐silencing levels similar to what was 
observed in human primary astrocytes cultures. 
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6.5 CNS Tumors 
In the CNS, diverse tumors can be found, which include various gliomas, meningioma, choroid plexus 
carcinoma, medulloblastoma, and others, depending on the localization and the cell type from which 
it arises. Some have a very poor prognosis, such as the glioblastoma multiforme, the most malignant 
form of brain tumors. The use of dendrimers as delivery vectors for anti‐cancer therapy, including 
brain tumors, is extensive, as previously referred. The radioisotope boron‐10 was one of the first 
cargos delivered by dendrimers to brain tumors90 and although the in vitro results were promising in 
vivo, the study showed no specificity to the brain tumor cells, which is crucial in tumor therapy, that 
is, the requirement for selective cancer cell targeting. Therefore, different strategies were then 
employed such as the use of VEGF co‐delivered in boronated dendrimers91 and, onwards, the use 
of selective tumor‐ targeting moieties became common in dendrimer‐ based anti‐ cancer 
therapies. Various agents have been delivered or co‐delivered with dendrimers, such as the 
cytotoxic drug methotrexate,66 Dox,50 docetaxel,[23] or paclitaxel.92 Also, therapeutic genes in 
brain cancer such as apoptin,93 interferon beta (IFN‐β),77 and pORF‐hTRAIL[24] have also been 
delivered through dendrimers. The latter study, performed by Jiang group, is particularly interesting 
because it proposed a co‐delivery system administered by i.v. injection, combining both gene and 
chemotherapy. Another interesting use for dendrimers in brain tumors is the application of 
polyvalent, dendrimer‐bearing, magnetic nanoparticles (“dendriworm”), to deliver EGFR siRNA in 
a transgenic murine model of glioblastoma.94 For dendriworms development, cystamine core G4 
PAMAM dendrimers were reduced, yielding thiol dendrons. Then, amine‐modified, cross‐linked 
strings of spherical iron oxide nanoparticles coated with a biocompatible polymer (Dextran), named 
“nanoworms”, were prepared. Finally, reduced dendrons and nanoworms were conjugated using the 
heterobifuctional SPDP linker.94 Initially, dendriworms were administered via tail vein injections, but 
in this manner they accumulated significantly in the lungs. Subsequently, dendriworms were applied 
by CED. This methodology is highly invasive; nevertheless, the delivered dendriworms could diffuse 
in the brain parenchyma and deliver siRNA into the tumor cells, leading to significant gene 
suppression. 
As already referred, a systemic delivery of dendrimers has been successful in various brain tumor 
models.[22, 75] A pharmacokinetic study using PAMAM ‐ OH dendrimers showed a tumor 
accumulation only 15 min after tail vein injection, and it reached a peak concentration at 8 hours. The 
presence of the fluorescently labelled dendrimers was sustained for at least 48 hours.[22] Moreover, 
the dendrimers homogeneously distributed throughout solid tumor and gradually accumulate in 
tumor‐associated microglia/macrophages, which might be relevant for the further delivery of 
immunomodulatory molecules. 
6.6 Spinal Cord Injury 
SCI after a mechanical trauma causes major disabilities in virtually all physical and functional systems. 
Furthermore, the majority of affected people are young adults, which puts extra pressure in the 
treatment and rehabilitation process. Various therapies are in the forefront trials and, as recently 
stated, the therapy should encompass a combinatorial approach to a recognized multifactorial 
problem.95 A dendrimer‐based nanomedicine approach with all the advantages previously stated 
may be the most appropriate choice in SCI because it can offer multifunction abilities. Nevertheless, 
such studies have not been explored much to date. 
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In the literature, a surface ‐ engineered CMCht/PAMAM dendrimer was used to deliver a 
corticosteroid in a SCI animal model.96 This was performed by a local injection, 1 mm rostral and 1 
mm caudal, to the partially hemisected spinal cord lesion, which allowed for a sustained and 
controlled release in glial cells at the injury site for 14 days. There was also an improvement in the 
functional outcome of the injured rats. Before in vivo administration, cytotoxicity was evaluated 
without significant effects in non‐neuronal cells. 
Other studies are now anticipated in the area of SCI therapies using dendrimers as the deliver vector, 
possibly carrying a combination of therapies intended to achieve neuroprotection and/or 
neuroregeneration effects. 
6.7 Other CNS Disorders 
As observed in previous examples, the PAMAM dendrimers are usually the first choice as a delivery 
vector. In accordance, G4 PAMAM‐OH dendrimers have been applied in two rat models of retinal 
degeneration, resulting in cellular localization in activated microglia without the need of a cell specific 
ligand.[22] The drug fluocinolone acetonide, covalently conjugated to this dendrimer, as detailed 
above, was released in a sustained manner and, after a single retinal administration, dendrimers 
remained in the target cells for a remarkable period of over one month, effectively reducing 
inflammation. Such a controlled release is impressive and very appealing for this and other 
therapeutic purposes. 
6.8 Macromolecular Contrast Agents and Nanosensors 
Dendrimers are regarded in many different perspectives, depending on its function. Either they are 
being explored as vectors for delivery, antiviral agents, or even detoxifying compounds. Dendrimers 
have also been considered as macromolecular contrast agents and nanosensors for non‐invasive, 
advanced neuroimaging. This was explored in the field of CNS bioimaging, with an optical 
paramagnetic contrast agent based on a G5 PAMAM dendrimer, which was successfully applied in a 
glioblastoma mice model.97 Such use may have impact in delineating the brain tumor for surgical 
removal. Regarding potential brain tumor diagnosis applications, a more efficient contrast agent 
based on Gd‐DTPA for MRI that used DGLs was developed. For tumor specificity, the CTX peptide 
was used to target the nanoparticles, showing an ability to preferentially bind tumor cells. 
The application of dendrimers as nanosensors was demonstrated using a G2 PEG‐PAMAM for 
fluorescence sensing, which allowed monitoring changes of brain pH in vivo, as it was shown in a mice 
model of epilepsy.98 This new dendrimer‐based sensor can have various applications depending on 
the conjugated sensing fluorophores, which should be relevant for dynamic in vivo measurements of 
various CNS disorders. 
Also, a sodium‐sensing nanosensor was produced that demonstrated efficacy in imaging neuronal 
activity in brain slices65 and appeared better than available ion‐sensitive probes based on small 
fluorescent dyes. 
In a model of spinal cord contusion injury, the use of G1 fluorescent phosphorus‐based dendrimers 
was useful in following bone‐marrow‐derived macrophages because such dendrimers are readily 
internalized and maintained by these inflammatory cells. After injection at the subarachnoid space, 
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the macrophages were detected at the lesion site, and the dendrimers allowed assessing its 
phenotypic status because spectral changes in the phosphorus dendrimer emission profile were 
observed and related to the macrophage polarization physiology.99 
7 Challenges and Future Perspectives 
Dendrimers are nanosized materials that, due to their particular controlled globular structure, 
nanosize, multivalency, and low polydispersity are emerging in a large number of biomedical 
therapeutic applications. Besides the diagnosis and/or in vitro dendrimer‐based products already in 
the market, dendritic systems have already reached the clinical evaluation as contrast‐enhancer 
magnetic resonance imaging agents (Gadomer®‐17), anti‐microbicides (Vivagel®), and drug 
carriers for solid tumors therapy (DEP™ docetaxel). Notwithstanding, despite all these documented 
applications, the use of dendrimers within the CNS is still in its infancy and there are no reports of 
marketed products or current clinical trials using dendrimers for CNS diseases therapy. 
One of the most significant challenges in CNS disease therapy is the ability of therapeutic bioactives 
to permeate the BBB and reach CNS in an adequate bioavailability.100 Due to their controllable 
nanosize, several reports have recognized the ability of dendrimers to permeate this barrier and gain 
access to the CNS after systemic administration. Moreover, dendrimers have not only shown 
potential to act by itself as therapeutic or theranostic agents but also as vectors for the protection 
and delivery of bioactives to the CNS (as summarized in Table 1). However, the proper in vivo 
dendrimer biodistribution and safety profile is yet to be determined in depth, which may hinder their 
passage for clinical evaluation. 
Nonspecific dendrimer toxicity is closely related to its internal chemical composition, size, 
generation, and concentration, but it is mostly influenced by the nature of the surface terminal 
groups. In general, unmodified cationic dendrimers are more cytotoxic than their anionic or neutral 
counterparts.101 Likewise, higher concentrations and generations of unmodified cationic 
dendrimers display an inherently greater cationic surface charge and, therefore, a marked cytotoxic 
and hemolytic effect.102 However, there is still some inconsistency in the literature regarding the 
impact of the generation of a specific dendrimer on its toxicity profile. Namely, some authors have 
shown that low generations of PAMAM and PPI dendrimers are not toxic in vivo4, 103 (even if 
preliminary in vitro data has pointed to some toxicity profile),56 while others have reported a toxic 
profile for the same dendrimers.104 This stresses the need for optimizing the dendrimer 
composition, generation, dosage, and administration route, as well as to assess the safety and 
effectiveness at different time points after administration. 
Previous studies showed that unmodified cationic dendrimers, as well as other cationic 
macromolecules, strongly interact with the negatively charged cell membranes, which may 
destabilize membrane integrity followed by leakage of intracellular components that leads to cell 
death and toxicity.105 Moreover, when systemically administered, the cationic terminal groups of 
unmodified dendrimers can interact with red blood cells (RBCs), which may result in hemolysis. 
Similarly, such cationic dendrimers can also influence hematological parameters such as white blood 
cell (WBC) and RBC counts and morphology, hemoglobin content, and hematocrit and mean 
corpuscular hemoglobin (MCH) values.106 Thus, the prevention of strong electrostatic 
interactiTableons of dendrimers or bioactive/dendrimer system with cellular membranes by use of 
neutral or anionic dendrimers and/or by surface engineering (e.g., by the well‐known PEGylation 
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and/or carbohydrate coating) is a step that must be carefully considered to minimize nonspecific 
toxicity. 
For instance, Greish et al. compared the toxicity profile of hydroxyl and carboxyl‐ terminated 
PAMAM dendrimers with the amine‐terminated counterparts. Both neutral hydroxyl and anionic 
carboxyl‐terminated PAMAM dendrimers showed a decrease in their cytotoxic profile, with no 
evidence of causing protein opsonization or blood hemolysis, as compared to amine‐terminated 
PAMAM.[101] The same findings were corroborated by others.107 Overall, these studies 
demonstrate that the use of neutral and anionic dendrimers together with surface engineering 
strategies are key tools to enhance biocompatibility and reduce the overall immunogenicity of these 
systems. Additionally, another strategy capable of modulating the biocompatibility of dendritic 
systems is the optimization of their size. As previously discussed, the size of dendrimers or 
dendrimer/bioactive systems can be finely tuned to maximize, for example, the EPR effect or rapid in 
vivo clearance, accordingly to the proposed application. 
Dendrimers' biodistribution is predominantly modulated by their size and surface chemistry. While 
smaller dendrimers present short circulation times and are more quickly cleared by renal filtration, 
bigger dendrimers are slowly eliminated from the circulation and are more efficiently taken up by 
macrophages, leading to increased reticulo‐endothelial system (RES) clearance.108 Moreover, 
cationic dendrimers have the potential to interact more strongly with vasculature of highly perfused 
organs, which increases their clearance rate from the circulation as compared to anionic 
equivalents.[107] 
The above‐mentioned surface engineering with shielding agents or targeting ligands may not only 
aim at diminishing the charge‐dependent toxicity but also increase water solubility and circulation 
time (especially when systems modified with anti‐biofouling polymers, like PEG, are explored) 
while minimizing off‐target effects by enhancing the systems targeting potential and payload 
efficacy. For example, Zhu and co‐workers demonstrated that increasing the degree of PEGylation 
in PAMAM dendrimers can reduce liver and spleen accumulation and general toxicity, prolong the 
circulation time, and enhance the accumulation in tumor tissue of the PEGylated dendrimers 
conjugates, as compared to their unmodified equivalents.[22] The impact of dendrimer PEGylation 
on its biodistribution and circulation time was recently corroborated by Kojima et al.109 Moreover, 
other promising anti ‐ biofouling/non ‐ fouling polymers have recently emerged as possible 
alternatives to PEG, namely zwitterionic polymers,110 poly(2 ‐ oxazoline)s,[110, 111] 
poly(peptoids),[110] and poly(carbonates),112 among others. Although there are already a few works 
in which some of these polymers are linked to dendritic structures,[110, 111] further studies are 
expected to test the favorable properties of these alternative polymers when attached to dendrimers. 
Similarly, Kesharwani et al. compared the tumor targeting potential and respective toxicity profile of 
three different ligand‐conjugated PPI dendrimers with the corresponding plain (unmodified) PPI 
counterparts. They observed that the receptor conjugated PPI dendrimers not only showed 
enhanced tumor ‐ targeting potential, but also significantly diminished hemolytic toxicity as 
compared with the plain PPI dendrimers.113 
Within the CNS applications, the BBB permeation ability of dendrimers can be seen as a double‐
edged sword. While the enhanced BBB permeation may increase the bioavailability of therapeutic 
bioactives within the CNS, it can also increase the risks of overexposure of target cells to the 
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therapeutic bioactives and dendrimers and, consequently, result in CNS toxicity. This cell toxicity is a 
feature commonly associated with the use of non‐biodegradable dendrimers. Non‐biodegradable 
dendrimers have the potential for long‐term accumulation within lysosomes or cytoplasm and thus 
exhibit undesired cytotoxicity effects, which may be the case for reactive oxygen species (ROS) 
production and decreased metabolic activity.114 Therefore, to prevent dendrimer 
bioaccumulation‐associated toxicity, the use of biodegradable dendrimers is strongly encouraged 
in a biomedical scenario.115 Such dendrimers should degrade into smaller fragments under 
physiological conditions, which can be excreted or eliminated through metabolic pathways. 
Despite the intensive evaluation of dendrimers in the past few years, much research remains to be 
done to allow the ready translation of these nanoconstructs into clinically useful CNS nanomedicines. 
It is now clear that the potential benefit of dendrimers is closely linked to their physicochemical 
properties, which should be modulated in accordance with the proposed therapeutic application. 
However, this review clearly depicts the poor variability of dendrimer classes that underwent 
preclinical evaluation. For application in the CNS, the majority of the dendrimers used were based 
only in 3 main families: PAMAM, PPI, and PLL dendrimers. Consequently, future developments 
towards the design of more biocompatible and biodegradable dendrimers, novel linker technologies, 
as well as novel targeting agents that can collectively result in the improvement of dendrimer‐based 
systems bioavailability at the target tissues, are eagerly awaited. Furthermore, efforts on the 
development of efficient multigram synthesis to fulfill the pharmaceutical industry demand, as well 
as green synthetic routes, will also be important to the field. Minimizing the use and generation of 
hazardous substances would have an impact not only in environmental terms but would also 
contribute to improvements in terms of purification processes and biocompatibility. The design of 
such improved systems will therefore require additional efforts to better understand the 
dendrimer‐cell/body interaction, as well as their in vivo fate. Nevertheless, resolution and lack of 
sensitivity of currently available bioimaging tools remains a caveat when studying nanosystems 
behavior at the whole‐body scale.116 At present, the field has been limited to the evaluation of 
overall biodistribution/accumulation in key organs, time of clearance, systemic inflammatory 
reaction and associated toxicity. 
When considering the CNS, the possibility to explore several routes of administration (Figure 1) opens 
new avenues to improve the efficiency and, when applicable, the targeting of the treatment. 
However, for many neurological disorders the etiology and the specificities of the disease are yet 
poorly understood. So, the field will have to be constantly fed from the progress achieved at the 
fundamentals of neuroscience and neurology. 
All in all, successfully bringing forward dendrimers as powerful tools in the treatment of CNS diseases 
will definitely require a multi‐ and interdisciplinary effort due to the uniqueness and paramount 
importance of this system. 
In conclusion, dendrimers can be used in the CNS with various purposes, not only to deliver active 
therapeutic molecules but also to assess brain function and to diagnose CNS diseases or even to 
perform a combination of these purposes. Such a remarkable ability highlights their tremendous 
potential as a precise theranostic multifunctional agent, which we predict in the future to be 
extended to other unexplored CNS disorders. 
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Table 1. Overview of dendrimer applications in the context of the CNS 
Application 
Dendrimer 
family 
Targeting 
ligand 
Bioactive 
agent 
Remarks 
Reference
s 
Vascular diseases 
Ischemic stroke 
PAMAM 
(G2, G4) 
n.a. 
HMGB1 
siRNA, 
pHO‐1 
Reduction of 
infarction in the 
ischemic brain 
[22]  
 DGL (G3) 
Dermorphi
n 
anti‐Ask1 
shRNA 
Preferable 
accumulation and 
gene transfection 
in brain 
83 
    
Significant 
reduction of 
cerebral infarct 
area 
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Application 
Dendrimer 
family 
Targeting 
ligand 
Bioactive 
agent 
Remarks 
Reference
s 
Hypoxia‐mediated 
neurotoxicity 
Carbosilan
e (G2) 
n.a. 
HIF1‐α 
siRNA 
In vitro selective 
block of HIF 
[25]  
Hypothermic 
circulatory arrest 
PAMAM 
(G4) 
n.a. VPA, NAC 
Injured BBB 
crossing and 
localization in 
injured 
hippocampal 
dentate granule 
cells, cerebellar 
Purkinje and 
granule cells and 
microglia 
[22]  
    
Improvement of 
neurobehavioral 
outcomes 
 
Neurodegenerative diseases 
Alzheimer 
PPI (G4, 
G5) 
n.a. n.a. 
Bind to Aβ 
affecting its 
aggregation 
process and 
attenuate Aβ 
induced 
neurotoxicity both 
in vitro and in vivo 
[23]  
 
GATG (G3) 
   
29  
 
PAMAM 
(G0, G3, 
G4) 
   
86, 117 
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Application 
Dendrimer 
family 
Targeting 
ligand 
Bioactive 
agent 
Remarks 
Reference
s 
 Phosphoru
s (G3, G4) 
   [27]  
 DGL (G3, 
G5) 
   [24]  
Parkinson 
PAMAM 
(G5) 
Lf, 
Angiopep‐2 
phGDNF 
Brain‐targeted 
gene delivery 
promoted long‐
term and effective 
neuroprotection in 
a Parkinson 
disease animal 
model 
[22, 24, 75]  
 
DGL (G3) Angiopep‐2 phGDNF 
 
[24]  
Neuroimmunomodulation 
Cerebral palsy 
PAMAM 
(G4) 
n.a. NAC 
Accumulation in 
activated 
microglia and 
astrocytes 
[22]  
    
Suppression of 
neuroinflammatio
n accompanied 
with motor 
function 
improvement 
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Application 
Dendrimer 
family 
Targeting 
ligand 
Bioactive 
agent 
Remarks 
Reference
s 
Ischemia‐induced 
white matter injury 
PAMAM 
(G4) 
n.a. NAC 
Attenuation of the 
pro‐inflammatory 
response while not 
impacting the 
anti‐inflammatory 
response 
[22]  
Vaccines 
PETIM 
(G4) 
n.a. pIRES‐Rgp 
Produce an earlier 
onset of a high‐
tittered protective 
antibody response 
28  
Neuroinfection 
Prion disease 
PAMAM 
(G4, G5) 
n.a. n.a. 
General decrease 
of prion proteins, 
both in vitro and in 
vivo 
[22, 87, 88]  
 PPI (G4, 
G5) 
   
[22, 88]  
 
Phosphoru
s (G3, G4, 
G5) 
   
[27]  
HIV‐1 infection 
Carbosilan
e (G2) 
n.a. 
Rev AON, 
GEM91 
AON, anti‐
TAR AON, 
p24 siRNA, 
nef siRNA 
and Cox‐2 
siRNA 
General decrease 
of antiviral activity 
both in vitro and in 
vivo 
[25]  
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Application 
Dendrimer 
family 
Targeting 
ligand 
Bioactive 
agent 
Remarks 
Reference
s 
Cancer 
Glioma/Glioblastom
a 
PAMAM 
(G3, G4, 
G5) 
Tf/TAM, 
RGD, L8A4, 
EGF, C225, 
Tf/WGA, 
CTX, 
CREKA, 
arginine, 
Angiopep‐2 
Dox, MTX, 
B1100, 
PODO, EM, 
PTX, 
curcumin, 
pORF‐
TRAIL, 
pEGFP, 
pSiLuc, 
pRFP, 
pGL2, 
pGL3, 
pORF‐IFN‐
β, GFP 
siRNA, Luc 
siRNA, 
Enhanced 
penetration and 
accumulation in 
brain tumor tissue 
[22, 50, 52, 
66, 67, 73, 
75, 77, 92-
94, 118]  
    Anti‐tumor effect  
 PEPE (G2) 
D‐
glucosamin
e 
MTX  26  
 
PPI (G5) 
P80, 
thiamine 
DTX, PTX 
 
[23]  
 
DGL (G3) 
T7 peptide, 
cyclic RGD 
pORF‐
TRAIL, 
Dox, Luc 
siRNA 
 
[24]  
Spinal cord injury 
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Application 
Dendrimer 
family 
Targeting 
ligand 
Bioactive 
agent 
Remarks 
Reference
s 
Spinal cord 
hemisection 
PAMAM 
(G1.5) 
n.a. MP 
Effective 
improving of 
functional 
outcome after 
administration 
and 
internalization in 
the spinal cord 
tissue of partially 
hemisected rats 
96  
Other applications 
Retinal 
degeneration 
PAMAM 
(G4) 
n.a. FA 
Accumulation in 
the outer retina 
within activated 
microglia without 
active targeting 
[22]  
    
Neuroprotection 
with attenuation 
of 
neuroinflammatio
n 
 
BBB permeation 
and brain 
transfection 
PAMAM 
(G4, G5) 
Angiopep‐
2, Tf, Lf, 
RVG29 
pEGFP, 
pGL2, pCN‐
Luci, 
HMGB1 
shRNA 
Proof of concept: 
cellular 
endocytosis 
mechanism, in 
vitro BBB 
permeation ability 
and transfection 
efficiency 
[70, 71, 73-
75, 119]  
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Application 
Dendrimer 
family 
Targeting 
ligand 
Bioactive 
agent 
Remarks 
Reference
s 
 PPI (G3, 
G4) 
Tf 
pCMVsport 
β‐gal, 
pCMV‐
tdTomato 
 
[10, 23]  
 
DGL Leptin 30 pRFP 
 
[22]  
Toxicity 
PAMAM 
(G4) 
n.a. n.a. 
Proof of concept: 
in vitro and in vivo 
toxicity 
4, 78 
Contrast agents and nanosensors 
Contrast agents 
PAMAM 
(G5) 
Angiopep‐2 
Rhodamine
, Cy5.5 and 
Gd(III)‐
DOTA 
Conjugation of 
MR and optical 
reporters to be 
used as contrast 
agents. Ability to 
circumvent the 
blood brain 
barrier (BBB) and 
visualize brain 
tumors with high 
sensitivity in vivo 
97 
Sensor 
PAMAM 
(G2, G4.5, 
G5) 
n.a. 
Fluorescein
, 
rhodamine, 
CoroNa 
(Green or 
Red) 
Ability to monitor 
changes of 
neuronal activity 
and brain pH 
65, 98 
 Version: Postprint (identical content as published paper) This is a self-archived document from i3S – Instituto de 
Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our 
publications, please visit http://repositorio-aberto.up.pt/  
 
A
0
1
/0
0
 
Application 
Dendrimer 
family 
Targeting 
ligand 
Bioactive 
agent 
Remarks 
Reference
s 
 Phosphoru
s (G1) 
n.a. 
Fluorophor
e (Em 485 
nm) 
Ability to sensor 
macrophage 
phenotype 
99  
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